Corcept Therapeutics Increases FY23 Revenue From $455M-$470M To $470M-$480M Vs $465.62M Est.
Portfolio Pulse from Benzinga Newsdesk
Corcept Therapeutics has increased its FY23 revenue forecast from $455M-$470M to $470M-$480M, which is higher than the estimated $465.62M.
November 01, 2023 | 9:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Corcept Therapeutics' increased FY23 revenue forecast could potentially lead to a positive impact on its stock price.
Corcept Therapeutics has raised its FY23 revenue forecast, which is a positive signal for investors. This could lead to increased investor confidence and potentially a rise in the stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100